ROLE OF FGF23 IN THE PATHOGENESIS OF MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE

Abstract

Mineral and bone disorders in chronic kidney disease (CKD-MBD) are among the most common and severe complications in patients with renal insufficiency. Fibroblast Growth Factor 23 (FGF23) is an osteocytic hormone that regulates phosphate metabolism and vitamin D homeostasis. Its levels begin to rise in the early stages of CKD and have systemic effects on mineral balance. Excessive FGF23 production disrupts bone mineralization, exacerbates hypophosphatemia, reduces the synthesis of active vitamin D, and is associated with an increased risk of cardiovascular complications. Studying the role of FGF23 in the pathogenesis of CKD-MBD is of high clinical importance for diagnosis, monitoring, and therapeutic strategy selection.